Travere pays $112.5M upfront for Everest's kidney disease BTK drug

Travere Therapeutics is betting $1.14 billion on a Chinese-developed BTK inhibitor to anchor its rare kidney disease franchise.

Travere Therapeutics licensed Everest Medicines' civorebrutinib for $112.5 million upfront and up to $1.03 billion in development, regulatory and commercial milestones, adding a potential best-in-class BTK inhibitor to its rare kidney disease pipeline.

"The drug has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients," Travere CEO Eric Dube said in a statement, citing proof-of-concept data in primary membranous nephropathy and broad mechanistic applicability across diseases including FSGS and IgA nephropathy.

Civorebrutinib, an oral reversible BTK inhibitor, showed reductions in anti-PLA2R autoantibodies and proteinuria in a Phase 1/2 trial for primary membranous nephropathy, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. The deal covers all markets except Greater China and select East and Southeast Asian countries, with Travere paying tiered royalties in the high-single to double-digit range on future sales.

The agreement builds on Travere's momentum after the FDA approved Filspari in April as the first treatment for FSGS — a drug Leerink Partners analysts estimate could generate over $1 billion in peak sales. For Everest, the $112.5 million upfront validates its strategy of in-licensing Chinese assets and out-licensing them globally.

How Civorebrutinib Works

Civorebrutinib targets Bruton's tyrosine kinase, a key mediator of B-cell receptor signaling that controls B-cell activation, maturation and differentiation into antibody-producing cells. By inhibiting BTK, the drug aims to suppress the autoimmune response driving kidney damage in diseases such as primary membranous nephropathy, where autoantibodies attack the glomerular basement membrane. Everest originally licensed the asset from Sinovent and SinoMab in 2021 in a deal valued at $561 million in biobucks.

What the Deal Means for Both Companies

For Travere, civorebrutinib fills a pipeline gap beyond Filspari, which treats FSGS but leaves other immune-mediated kidney diseases unaddressed. The company now has a platform candidate it can develop across at least five indications, including IgA nephropathy and minimal change disease — markets where current standard of care relies on broad immunosuppressants with significant toxicity.

Everest, meanwhile, receives a $112.5 million upfront payment that strengthens its cash position while retaining rights in China and parts of Asia, where the kidney disease patient population is among the largest globally. The tiered royalty structure means Everest shares in upside if civorebrutinib reaches commercial sales.

Travere shares traded higher following the announcement. The company's Filspari approval in April marked a turnaround after a negative Phase 3 readout and a three-month FDA review extension. Analysts at Leerink have said Filspari represents a sales opportunity exceeding $1 billion, giving Travere a revenue base to fund civorebrutinib's development across multiple indications.

This article is for informational purposes only and does not constitute investment advice.